Revvity Short Interest Eases Into Earnings as Peers Diverge

RVTY is the least crowded name in a peer group where short pressure has been far more aggressive, with short interest down 7.2% over the past week to 5.3% of free float. That compares to a week where ILMN shed 18.6% in a single session and FTRE dropped 9.9%, with broader sector moves suggesting life sciences tools names are absorbing considerable selling pressure into this reporting season.

Revvity's own short position has actually been retreating since mid-October, when it peaked near 6.8 million shares. The weekly decline of 7.2% is roughly 1.5 standard deviations below the company's typical weekly move over the past year, meaning shorts are covering at a faster clip than usual, not adding. Borrowing costs have also eased, now at 0.42% and down about 9% on the week, a low rate by any measure. Availability in the lending market is loose, with around 582% availability relative to outstanding short interest, well above its 52-week trough of 156%. The borrow market offers no signal of short-seller conviction here.

The debate going into Monday's print centres on whether Revvity can prove its top two segments are genuinely accelerating. Bears point to Immunodiagnostics ex-China running at mid-to-high single-digit growth versus a 9% to 11% target, and Life Sciences only now returning to low-single-digit growth after two years of contraction. Euroimmun and BioLegend have both lost momentum. Bulls counter with the portfolio's ~80% recurring revenue, the 11% organic growth Diagnostics posted in Q2, and management's track record of raising FY26 organic growth guidance from 2-3% to 4-5%. TD Cowen lifted its target to $175 from $130 in mid-October while holding a Buy rating; Barclays also raised to $160 from $115, though only at Equal-Weight. The analyst consensus mean target of $147 now sits below the current price of $157, a rare configuration that reflects how sharply the stock has run, up over 60% year to date, rather than outright bearishness from the Street.

T. Rowe Price is the defining ownership fact here. Between two affiliated entities it holds more than 20% of the company, and T. Rowe Price Associates filed a 13G/A in early October showing its stake had grown from 5% to 11.8%. That concentration means any shift in T. Rowe's view would be felt in the share price. EdgePoint, also a passive 13G holder, last reported 7.4% and has been building steadily.

The November 3 print will test whether the company's organic growth trajectory in Immunodiagnostics and Life Sciences Solutions has actually inflected, or whether the year-to-date re-rating has run well ahead of the fundamental evidence.